Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

(2015) Michael Doubek et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

(2015) Anders Österborg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

(2015) Peter Hillmen et al.   LANCET

Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial

(2014) Michelle Furtado et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Ofatumumab: a novel treatment for severe systemic lupus erythematosus

(2014) C. C. Thornton et al.   RHEUMATOLOGY

Anti–B Cell Antibody Therapies for Inflammatory Rheumatic Diseases

(2013) Mikkel Faurschou et al.   Annual Review of Medicine

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

(2013) Bertrand Coiffier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

(2013) Tait Shanafelt et al.   CANCER

Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

(2013) R. Kurrasch et al.   JOURNAL OF RHEUMATOLOGY

Emerging injectable therapies for multiple sclerosis

(2013) Jiwon Oh et al.   LANCET NEUROLOGY

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

(2012) M. S. Czuczman et al.   BLOOD

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

(2011) P. C. Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

(2010) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM